Cargando…

Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B

BACKGROUND/AIMS: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient’s number. A large-scale nation-wide real-world surveillance study was carried o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Chang Wook, Kim, Chang Seop, Kim, Hee Yeon, Lee, Chang Don, Yu, Kyungha, Llamoso, Cyril, Lee, Heon Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768541/ https://www.ncbi.nlm.nih.gov/pubmed/29228519 http://dx.doi.org/10.3904/kjim.2016.111

Ejemplares similares

The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B
por: Tang, Hong, et al.
Publicado: (2013)

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
por: Lee, Kwan Sik, et al.
Publicado: (2017)

Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study
por: Kim, Jihye, et al.
Publicado: (2023)

Entecavir and Hepatitis B Immune Globulin in Patients Undergoing Liver Transplantation for Chronic Hepatitis B
por: Perrillo, Robert, et al.
Publicado: (2013)

Antiviral Efficacy of Entecavir versus Entecavir plus Adefovir for Hepatitis B Virus rtA181V/T Mutants Alone
por: Oh, Myung Jin, et al.
Publicado: (2016)

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
por: Choi, Han Na, et al.
Publicado: (2015)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B
por: Song, Joon Chang, et al.
Publicado: (2011)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
por: Lee, Kyung Jae, et al.
Publicado: (2018)

Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response
por: Kwon, Dae Hun, et al.
Publicado: (2013)

Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir
por: Jo, Yu Jung, et al.
Publicado: (2015)

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Kim, Jung Hee, et al.
Publicado: (2016)

Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study
por: Yao, Guangbi, et al.
Publicado: (2008)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
por: Ahn, Sang Hoon, et al.
Publicado: (2013)

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
por: An, Jihyun, et al.
Publicado: (2017)

Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection
por: Chung, Won Gil, et al.
Publicado: (2012)

High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
por: Chae, Hee Bok, et al.
Publicado: (2012)

Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients
por: Kim, Sang Jin, et al.
Publicado: (2020)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
por: Jun, Dae Won, et al.
Publicado: (2013)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
por: Lee, Jaemin, et al.
Publicado: (2016)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir
por: Lu, Yu-Xia, et al.
Publicado: (2021)

Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
por: Cho, Young Youn, et al.
Publicado: (2020)

Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A
por: Cho, Hyosun, et al.
Publicado: (2016)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis
por: Jwa, Hye Young, et al.
Publicado: (2016)

A Decade-old Change in the Screening Rate for Hepatocellular Carcinoma Among a Hepatitis B Virus-infected Population in Korea
por: Kim, Hee Yeon, et al.
Publicado: (2016)

Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial
por: Cho, Eun Ju, et al.
Publicado: (2018)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Hepatitis B Core Antigen Expression in Hepatocytes Reflects Viral Response to Entecavir in Chronic Hepatitis B Patients
por: Lee, Jeong Guil, et al.
Publicado: (2013)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

Development of a Modified Korean Version of the Epworth Sleepiness Scale Reflecting Korean Sociocultural Lifestyle
por: Jung, Seo-Yeon, et al.
Publicado: (2018)

Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis
por: Shin, Seung Kak, et al.
Publicado: (2021)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Severe Acute Hepatitis B Treated With Entecavir.
por: De Socio, Giuseppe Vittorio Luigi, et al.
Publicado: (2011)

Reliability and Validity of the Korean Version of the Empathy Quotient Scale
por: Kim, JuHee, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_iuslpp4i7b5vfplfuss2a9hu46